[1]Patschan D,Muller GA.Acute Kidney Injury in Diabetes Mellitus.Int J Nephrol.2016;2016: 6232909.[2]Riddy DM,Delerive P, Summers RJ, et al. G Protein-Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus.Pharmacol Rev.2018;70(1): 39-67.[3]Maleckas A,Venclauskas L,Wallenius V,et al.Surgery in the treatment of type 2 diabetes mellitus. Scand J Surg.2015;104(1): 40-47.[4]中华医学会糖尿病分会.中国2型糖尿病防治指南(2017年版)[J].中国实用内科杂志,2018,38(4): 292-344.[5]中华医学会糖尿病分会.中国2型糖尿病防治指南(2013年版) [J].中国医学前沿杂志(电子版),2017, 7(3): 26-88.[6]Liang S,Cai GY,Chen XM.Clinical and pathological factors associated with progression of diabetic nephropathy. Nephrology (Carlton).2017;22 Suppl 4:14-19.[7]Chen ZJ,Ma F,Sun XM,et al.Renoprotective Effect of a Chinese Herbal Formula, Qidan Dihuang Decoction, on Streptozotocin-Induced Diabetes in Rat. Evid Based Complement Alternat Med.2018; 2018: 7321086.[8]Dong H, Zhou Y, Wang Y, et al. The protective role of intermedin in promoting angiogenesis during renal fibrosis.Gene.2018;688: 34-43.[9]Nguyen-Thanh T,Kim D,Lee S,et al.Inhibition of histone deacetylase 1 ameliorates renal tubulointerstitial fibrosis via modulation of inflammation and extracellular matrix gene transcription in mice.Int J Mol Med.2018;41(1):95-106.[10]Carranza K, Veron D, Cercado A, et al. Cellular and molecular aspects of diabetic nephropathy; the role of VEGF-A.Nefrologia. 2015;35(2): 131-138.[11]D'Arpino MC,Fuchs AG,Sanchez SS,et al.Extracellular matrix remodeling and TGF-beta1/Smad signaling in diabetic colon mucosa.Cell Biol Int.2018;42(4): 443-456.[12]Kanta J.Collagen matrix as a tool in studying fibroblastic cell behavior.Cell Adh Migr.2015; 9(4): 308-316.[13]Kawanami D,Matoba K,Takeda Y,et al.SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy.Int J Mol Sci. 2017;18(5).[14]DeFronzo RA,Ferrannini E,Groop L, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers.2015; 1: 15019.[15]Kao KT,Sabin MA.Type 2 diabetes mellitus in children and adolescents. Aust Fam Physician.2016;45(6):401-406.[16]仝小林,倪青,魏军平,等.糖尿病中医诊疗标准[J].世界中西医结合杂志,2011,6(6)540-547.[17]朱章志,裴倩.扶阳法治疗糖尿病[J]. 药品评价,2009,6(12):471-472.[18]武文慧,裴香萍,门九章,等.门九章运用理中汤加味治疗放化疗后呕吐经验[J].湖北中医杂志,2018, 40(4): 18-20.[19]国家中医药管理局医政司. 24个专业92个病种中医诊疗方案[M].北京:中国医药科技出版社,2017:194.[20]张广梅,李杰,吴萍,等.血清D-木糖与太阴病(脾阳虚证)“欲解时”及理中汤干预的研究[J].中华中医药杂志,2018,33(10): 4685-4688.[21]吴水生,郭改革,李长伟,等.中药“疾病缩减效应”假说与理中丸抗消化性溃疡多成分多靶点整合协同作用的实验验证[J].世界科学技术(中医药现代化),2010,12(4): 580-584.[22]段永强,程卫东,李兰珍,等.四君子汤和理中汤对脾虚肠易激综合征大鼠一氧化氮信号通路及胃动素表达影响的差异[J].中国老年学杂志,2014,(18): 5148-5151.[23]周晓玲,唐农,余静芳,等.理中汤对肝硬化大鼠肠道微生态的影响[J].辽宁中医杂志,2018,45(7): 1521-1525.[24]陈丽艳,陈鹏,孙银玲,等.玉米须对2型糖尿病模型大鼠降糖机制研究[J].中华中医药杂志, 2016, 31(10): 4253-4255.[25]施红,金国琴,余文珍.诱导构建最佳类似人类2型糖尿病大鼠的造模方式[J].中国组织工程研究,2005, 9(39): 69-71.[26]桂莉, 郭家智, 曹梅,等.高脂?高胆固醇灌胃诱导2型糖尿病SD大鼠模型的实验研究.昆明医学院学报,2010, 31(10): 41-44.[27]张松筠,杨长春,郝咏梅,等. 食源性肥胖大鼠2型糖尿病模型的建立[J].中国组织工程研究,2010, 14(28): 5212-5215.[28]Levin BE, Hogan S, Sullivan AC. Initiation and perpetuation of obesity and obesity resistance in rats. Am J Physiol.1989;256(3 Pt 2): R766-771.[29]Levin BE, Dunn-Meynell AA,Balkan B,et al.Selective breeding for diet-induced obesity and resistance in Sprague-Dawley rats. Am J Physiol.1997;273(2 Pt 2): R725-730.[30]陈凤丽,曹晨,孙亦农,等.高脂饲料诱发大鼠肥胖模型的实验研究[J].辽宁中医杂志,2015,42(9):1792-1794.[31]Zhang S, Xu H, Yu X, et al. Metformin ameliorates diabetic nephropathy in a rat model of low-dose streptozotocin-induced diabetes.Exp Ther Med.2017;14(1):383-390.[32]Chen P,Shi X, Xu X,et al.Liraglutide ameliorates early renal injury by the activation of renal FoxO1 in a type 2 diabetic kidney disease rat model.Diabetes Res Clin Pract.2018;137: 173-182.[33]Sugano M,Yamato H,Hayashi T,et al.High-fat diet in low-dose- streptozotocin-treated heminephrectomized rats induces all features of human type 2 diabetic nephropathy: a new rat model of diabetic nephropathy.Nutr Metab Cardiovasc Dis. 2006;16(7): 477-484.[34]Kim Y, Park CW. Adenosine monophosphate–activated protein kinase in diabetic nephropathy. Kidney Res Clin Pract. 2016;35(2): 69-77.[35]Dugbartey GJ.Diabetic nephropathy: A potential savior with 'rotten-egg' smell.Pharmacol Rep. 2017;69(2): 331-339.[36]Liu C,Feng X,Li Q,et al.Adiponectin, TNF-alpha and inflammatory cytokines and risk of type 2 diabetes: A systematic review and meta-analysis.Cytokine.2016;86: 100-109.[37]林子桐,张超,沈雪梅.糖尿病肾病发病机制研究进展[J].中国药理学与毒理学杂志,2014,28(5): 765-773.[38]Almeida J, Mello V, Canani L, et al. Role of dietary lipids in diabetic nephropathy. Arq Bras Endocrinol Metabol.2009;53(5): 634-645.[39]Gin H, Rigalleau V, Aparicio M. Lipids, protein intake, and diabetic nephropathy.Diabetes Metab. 2000;26: 45-53.[40]Zhang L,Chen Z,Gong W,et al.Paeonol Ameliorates Diabetic Renal Fibrosis Through Promoting the Activation of the Nrf2/ARE Pathway via Up-Regulating Sirt1. Front Pharmacol.2018;9: 512.[41]Kinashi H, Ito Y, Sun T, et al. Roles of the TGF-beta(-)VEGF-C Pathway in Fibrosis-Related Lymphangiogenesis. Int J Mol Sci. 2018;19(9). pii: E2487.[42]Tetiko?lu M, Yüksel Z, Aktas S, et al. VEGF-A gene polymorphisms and responses to intravitreal ranibizumab treatment in patients with diabetic macular edema. Int Ophthalmol. 2018;38(6):2381-2388. [43]Chellini F, Tani A, Vallone L, et al. Platelet-Rich Plasma Prevents In Vitro Transforming Growth Factor-beta1-Induced Fibroblast to Myofibroblast Transition: Involvement of Vascular Endothelial Growth Factor (VEGF)-A/VEGF Receptor-1-Mediated Signaling (dagger). Cells. 2018;7(9). pii: E142.[44]Wei J, Jiang H, Gao H, et al. Blocking Mammalian Target of Rapamycin (mTOR) Attenuates HIF-1alpha Pathways Engaged-Vascular Endothelial Growth Factor (VEGF) in Diabetic Retinopathy.Cell Physiol Biochem.2016;40(6):1570-1577.[45]Mortuza R,Feng B,Chakrabarti S.SIRT1 reduction causes renal and retinal injury in diabetes through endothelin 1 and transforming growth factor β1. J Cell Mol Med. 2015;19(8): 1857-1867.[46]王劲松. TGF-β1?CTGF在增生性糖尿病视网膜病变患者血清中的表达及意义[J].临床眼科杂志,2014, 22(5): 464-466.[47]贾会玉,李中南,陈光亮.转化生长因子-β1介导的Smads和MAPKs信号通路在糖尿病肾病中的作用及其抑制剂研究进展[J].中国临床药理学与治疗学,2015,20(10):1171-1176.[48]Genovese F,Manresa AA,Leeming DJ,et al.The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis?.Fibrogenesis Tissue Repair.2014;7(1): 1-12. |